《大行》花旗：康方生物(09926.HK)HARMONi-2總生存期優效強化ivonescimab差異化優勢

阿斯達克財經

09/14

花旗發表研究報告指，康方生物(09926.HK) 的HARMONi-2中期讀數顯示，ivonescimab作為PD-L1陽性非小細胞肺癌一線單藥治療，對比pembrolizumab展現有意義的總生存期優效，強化其差異化定位，全球讀數仍是關鍵。該行指出，HARMONi-2在234宗總生存期事件下，ivonescimab的中位總生存期為30.75個月(pembrolizumab為22.57個月，風險...

網頁鏈接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hant/news/2667632069"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2667632069\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2667632069?lang=zh_TW&edition=fundamental","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20200914151046636_s.jpg","is_english":false,"pubTime":"2026-09-14 12:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2667632069","market":"other","top_or_hot":-1,"title":"《大行》花旗：康方生物(09926.HK)HARMONi-2總生存期優效強化ivonescimab差異化優勢","media":"阿斯達克財經","content":"<div>\n<p>花旗發表研究報告指，康方生物(09926.HK) 的HARMONi-2中期讀數顯示，ivonescimab作為PD-L1陽性非小細胞肺癌一線單藥治療，對比pembrolizumab展現有意義的總生存期優效，強化其差異化定位，全球讀數仍是關鍵。該行指出，HARMONi-2在234宗總生存期事件下，ivonescimab的中位總生存期為30.75個月(pembrolizumab為22.57個月，風險...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1544280/latest-news/AAFN\">網頁鏈接</a>\n\n</div>\n","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>《大行》花旗：康方生物(09926.HK)HARMONi-2總生存期優效強化ivonescimab差異化優勢</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n《大行》花旗：康方生物(09926.HK)HARMONi-2總生存期優效強化ivonescimab差異化優勢\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">阿斯達克財經</strong><span class=\"h-time small\">2026-09-14 12:14</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>花旗發表研究報告指，康方生物(09926.HK) 的HARMONi-2中期讀數顯示，ivonescimab作為PD-L1陽性非小細胞肺癌一線單藥治療，對比pembrolizumab展現有意義的總生存期優效，強化其差異化定位，全球讀數仍是關鍵。該行指出，HARMONi-2在234宗總生存期事件下，ivonescimab的中位總生存期為30.75個月(pembrolizumab為22.57個月，風險...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1544280/latest-news/AAFN\">網頁鏈接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1544280/latest-news/AAFN\">阿斯達克財經</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0348783233.USD","symbol_name":"安聯東方收入型 CI A Dis美元","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1544280/latest-news/AAFN","article_id":"2667632069","we_media_id":null,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20200914151046636_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1544280/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2667632069","pubTimestamp":1789359240,"columns":[],"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"花旗發表研究報告指，康方生物的HARMONi-2中期讀數顯示，ivonescimab作為PD-L1陽性非小細胞肺癌一線單藥治療，對比pembrolizumab展現有意義的總生存期優效，強化其差異化定位，全球讀數仍是關鍵。該行指出，HARMONi-2在234宗總生存期事件下，ivonescimab的中位總生存期為30.75個月；總生存期獲益在PD-L1 TPS > 50%及鱗狀非小細胞肺癌，整體存活期獲益最為明顯，安全性大致相若。該行維持康方生物「買入」評級，目標價171港元不變。","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0348783233.USD":"安联东方收入型 CI A Dis美元","LU2476274308.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (USD) ACC","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","LU0348767384.USD":"ALLIANZLITTLE DRAGONS \"A\" (USD) ACC","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","LU0417516571.SGD":"Allianz Oriental Income Cl AT Acc SGD","LU2399975544.HKD":"ALLIANZ ALL CHINA EQUITY \"AT\" (HKD) ACC","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","LU1961090484.USD":"ALLIANZ ALL CHINA EQUITY \"A\" (USD) INC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU0348827113.USD":"ALLIANZ RCM CHINA \"AT\" ACC","LU2476274720.SGD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (SGDHDG) ACC","KURE":"KraneShares MSCI All China Health Care Index ETF","BK1161":"生物科技","LU0348766576.USD":"ALLIANZ LITTLE DRAGONS \"A\" (USD) INC","BK1574":"生物医药B类股","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","LU0348784397.USD":"ALLIANZ ORIENTAL INCOME \"A\" (USD) ACC","LU0634319403.HKD":"ALLIANZ HONG KONG EQUITY \"AT\" (HKD) ACC","LU2778985437.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"A\" (USD) INC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","09926":"康方生物","LU1720050803.USD":"安联全方位中国股票基金","IE00BPRC5H50.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC","LU0540923850.HKD":"ALLIANZ HONG KONG EQUITY \"A\" (HKD) INC","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU0561508036.HKD":"ALLIANZ CHINA EQUITY \"A\" (HKD) INC","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC"},"translate_title":"Citigroup: Akeso Biologics (09926.HK) HARMONi-2's superior overall survival strengthens ivonescimab's differentiated advantage.","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1.5,"KURE":0.6},"content_text":"花旗發表研究報告指，康方生物(09926.HK) 的HARMONi-2中期讀數顯示，ivonescimab作為PD-L1陽性非小細胞肺癌一線單藥治療，對比pembrolizumab展現有意義的總生存期優效，強化其差異化定位，全球讀數仍是關鍵。該行指出，HARMONi-2在234宗總生存期事件下，ivonescimab的中位總生存期為30.75個月(pembrolizumab為22.57個月，風險比為0.73)；總生存期獲益在PD-L1 TPS > 50%(風險比0.58)及鱗狀非小細胞肺癌(風險比0.65)，整體存活期獲益最為明顯，安全性大致相若。該行對全球HARMONi-7在PD-L1高表達人群、以及全球鱗狀非小細胞肺癌人群持正面看法，並看好該公司未來試驗由中國走向全球的轉化；下半年關鍵催化劑包括處方藥用户付費法案(PDUFA)決定及HARMONi-3讀數。該行維持康方生物「買入」評級，目標價171港元不變。(su/ad)(港股報價延遲最少十五分鐘。沽空資料截至 2026-09-11 16:25。)AASTOCKS新聞","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}